Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

New England Journal of Medicine · 2013 · 5.2K citations · Full text

Medicine, Genetics, Molecular Genetics +12

Selective inhibition of BET bromodomains

P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +5

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Johannes Zuber, Junwei Shi, Eric Wang et al. · Nature · 2011 · 1.9K citations

Life Sciences, Molecular Biology, Molecular Genetics +9

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15